BioCentury | Sep 11, 2020
Translation in Brief

A compound to reduce adjuvanted vaccine side effects; an oncolytic virus to enable CAR T cells for solid tumors and more

Limiting the inflammatory side effects of adjuvanted vaccinesA team led by University of Chicago scientists reported in Science Advances that NF-κB modulator SN50 could enable the use of adjuvants to amplify adaptive immune response by...
BioCentury | Aug 29, 2020
Product Development

Next-wave Th1 cytokine cancer therapies aim for more precise targeting

A growing list of cytokine therapies have been designed to boost cytotoxic immune responses against cancer while sidestepping the limitations of past candidates by controlling where the molecules do and...
BioCentury | Aug 11, 2020
Deals

After Verrica deal in dermatological cancer, Lytix looks ahead to next-generation oncology product

Norwegian biotech Lytix has found a partner for its lead program in dermatological cancers, affording it the opportunity to continue that product’s development in additional indications while also moving ahead with a preclinical small molecule...
BioCentury | Aug 8, 2020
Management Tracks

PacBio shifts executive team; plus changes at CMAB, Valo, Alentis, Amwell and more

Pacific Biosciences of California Inc. (NASDAQ:PACB) announced a series of management changes Friday. Chairman Christian Henry will become president and CEO, effective Sept. 14. John Milligan, a member of the sequencing company’s board, will succeed...
BioCentury | Jul 25, 2020
Management Tracks

New CFOs for Generation Bio, IQVia; plus changes at Gracell, AskBio, Replimune, Triplet, Twist, Cellectis, Verrica and more

Fresh off its $200 million IPO last month, Generation Bio Co. (NASDAQ:GBIO) has added Matthew Norkunas as CFO. Norkunas, who succeeds interim CFO Stephen DiPalma, was CFO of SomaLogic Inc. IQVia Holdings Inc. (NYSE:IQV) has...
BioCentury | Jul 3, 2020
Management Tracks

Angus Grant joins BeiGene; plus changes at Sarepta, RegenxBio, BioMarin, Novavax, Whitehead, Akcea and more

BeiGene Ltd. (NASDAQ:BGNE; HKEX:6160) hired Angus Grant as chief business executive, a new position at the cancer company. He was CEO of the Dementia Discovery Fund. After eight years with Sarepta Therapeutics Inc. (NASDAQ:SRPT), EVP,...
BioCentury | Jun 18, 2020
Finance

June 17 Quick Takes: Constellation, Celldex raise follow-ons; plus CureVac quiet on IPO chatter and venture cash for GreenLight, TILT, DiogenX

Constellation raises close to $200M Cancer epigenetics company Constellation Pharmaceuticals Inc. (NASDAQ:CNST) raised $192.5 million in a bumped-up follow-on Tuesday through the sale of 5.5 million shares at $35. The price is a 7% discount...
BioCentury | Jun 16, 2020
Finance

June 15 Quick Takes: RA makes $200M investment in Novavax; plus venture rounds for Shattuck, ImmVira, Glyscend and Shukun

RA Capital to fund Novavax Novavax Inc. (NASDAQ:NVAX) said Monday it will raise $200 million through a private placement of 4.4 million shares at $45.57, its closing price on Friday, to RA Capital Management. The...
BioCentury | Jun 13, 2020
Product Development

Where companies see opportunity in the crowded PD-1 marketplace

Everyone wants a piece of the PD-1 pie, but as Merck continues to snap up new indications for Keytruda and the number of competitors grows, carving out niches in the competitive landscape is becoming increasingly...
BioCentury | Jun 6, 2020
Management Tracks

COVID-19 vaccine partners Lonza and Moderna announce new execs; plus Samumed, EpicentRx, Immatics, Aligos, ImmunoGen, Ferring, Sanifit and more

Pierre-Alain Ruffieux will become CEO of Lonza Group Ltd. (SIX:LONN), effective Nov. 1. He succeeds Chairman Albert Baehny, who had been serving on an interim basis since former CEO Marc Funk stepped down in January....
Items per page:
1 - 10 of 548
BioCentury | Sep 11, 2020
Translation in Brief

A compound to reduce adjuvanted vaccine side effects; an oncolytic virus to enable CAR T cells for solid tumors and more

Limiting the inflammatory side effects of adjuvanted vaccinesA team led by University of Chicago scientists reported in Science Advances that NF-κB modulator SN50 could enable the use of adjuvants to amplify adaptive immune response by...
BioCentury | Aug 29, 2020
Product Development

Next-wave Th1 cytokine cancer therapies aim for more precise targeting

A growing list of cytokine therapies have been designed to boost cytotoxic immune responses against cancer while sidestepping the limitations of past candidates by controlling where the molecules do and...
BioCentury | Aug 11, 2020
Deals

After Verrica deal in dermatological cancer, Lytix looks ahead to next-generation oncology product

Norwegian biotech Lytix has found a partner for its lead program in dermatological cancers, affording it the opportunity to continue that product’s development in additional indications while also moving ahead with a preclinical small molecule...
BioCentury | Aug 8, 2020
Management Tracks

PacBio shifts executive team; plus changes at CMAB, Valo, Alentis, Amwell and more

Pacific Biosciences of California Inc. (NASDAQ:PACB) announced a series of management changes Friday. Chairman Christian Henry will become president and CEO, effective Sept. 14. John Milligan, a member of the sequencing company’s board, will succeed...
BioCentury | Jul 25, 2020
Management Tracks

New CFOs for Generation Bio, IQVia; plus changes at Gracell, AskBio, Replimune, Triplet, Twist, Cellectis, Verrica and more

Fresh off its $200 million IPO last month, Generation Bio Co. (NASDAQ:GBIO) has added Matthew Norkunas as CFO. Norkunas, who succeeds interim CFO Stephen DiPalma, was CFO of SomaLogic Inc. IQVia Holdings Inc. (NYSE:IQV) has...
BioCentury | Jul 3, 2020
Management Tracks

Angus Grant joins BeiGene; plus changes at Sarepta, RegenxBio, BioMarin, Novavax, Whitehead, Akcea and more

BeiGene Ltd. (NASDAQ:BGNE; HKEX:6160) hired Angus Grant as chief business executive, a new position at the cancer company. He was CEO of the Dementia Discovery Fund. After eight years with Sarepta Therapeutics Inc. (NASDAQ:SRPT), EVP,...
BioCentury | Jun 18, 2020
Finance

June 17 Quick Takes: Constellation, Celldex raise follow-ons; plus CureVac quiet on IPO chatter and venture cash for GreenLight, TILT, DiogenX

Constellation raises close to $200M Cancer epigenetics company Constellation Pharmaceuticals Inc. (NASDAQ:CNST) raised $192.5 million in a bumped-up follow-on Tuesday through the sale of 5.5 million shares at $35. The price is a 7% discount...
BioCentury | Jun 16, 2020
Finance

June 15 Quick Takes: RA makes $200M investment in Novavax; plus venture rounds for Shattuck, ImmVira, Glyscend and Shukun

RA Capital to fund Novavax Novavax Inc. (NASDAQ:NVAX) said Monday it will raise $200 million through a private placement of 4.4 million shares at $45.57, its closing price on Friday, to RA Capital Management. The...
BioCentury | Jun 13, 2020
Product Development

Where companies see opportunity in the crowded PD-1 marketplace

Everyone wants a piece of the PD-1 pie, but as Merck continues to snap up new indications for Keytruda and the number of competitors grows, carving out niches in the competitive landscape is becoming increasingly...
BioCentury | Jun 6, 2020
Management Tracks

COVID-19 vaccine partners Lonza and Moderna announce new execs; plus Samumed, EpicentRx, Immatics, Aligos, ImmunoGen, Ferring, Sanifit and more

Pierre-Alain Ruffieux will become CEO of Lonza Group Ltd. (SIX:LONN), effective Nov. 1. He succeeds Chairman Albert Baehny, who had been serving on an interim basis since former CEO Marc Funk stepped down in January....
Items per page:
1 - 10 of 548